Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 17/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14848963 | 0.88 | CYP46A1 (0.79) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14840742 | 0.88 | CYP46A1 (0.57) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14848971 | 0.86 | CYP46A1 (0.79) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14849020 | 0.86 | CYP46A1 (0.69) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14849026 | 0.82 | CYP46A1 (0.75) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14841086 | 0.81 | CYP46A1 (0.62) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14840945 | 0.81 | CYP46A1 (0.58) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14849036 | 0.81 | CYP46A1 (0.79) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14840265 | 0.81 | CYP46A1 (0.61) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14849031 | 0.81 | CYP46A1 (0.85) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440990-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9440990-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150376205-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150376205-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376205-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PSEN1, HTT | CYP46A1 3483/4885CYP3A4 4115/4885CYP2C8 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.